Abstract: The present invention provides methods for treating interstitial lung diseases, comprising administering to an individual an effective amount of an inhibitor of coagulation factor XII. The invention further provides uses and pharmaceutical kits for that treatment.

Abstract: The present invention provides methods for treating interstitial lung diseases, comprising administering to an individual an effective amount of an inhibitor of coagulation factor XII. The invention further provides uses and pharmaceutical kits for that treatment.

Abstract: A monoclonal antibody which inhibits the blood clotting factor VII-activating protease and its proenzyme and a blood clotting factor VII-activating protease, stabilized by the addition of said monoclonal antibody, and its proenzyme are described. A suitable monoclonal antibody is produced by hybridoma cell line DSM ACC 2533. The application of the inhibitory, monoclonal antibody in the stabilization of blood clotting preparations and in preparations for reducing the coagulability of the blood is disclosed.

Abstract: Pharmaceutical preparations which comprise RNA or one or more coagulation-promoting fragments of RNA in amounts sufficient to promote coagulation and to promote fibrinolysis are described.

Abstract: Pharmaceutical preparations which comprise RNA or one or more coagulation-promoting fragments of RNA in amounts sufficient to promote coagulation and to promote fibrinolysis are described. They are in particular advantageously employed together with an activator for hemostatic processes such as factor VII-activating protease (FSAP).

Abstract: The present invention relates to the inhibition of angiogenesis by neutrophil alpha-defensins. Further, the present invention relates to methods involving the inhibition of endothelial cell adhesion to the extracellular matrix, endothelial cell apoptosis, and endothelial cell angiogenesis.mediated by alpha-defensins. b) instructions for the use of said ?-defensin for the purpose of modulating a biological process associated with said endothelial cell.

Abstract: Pharmaceutical preparations which comprise RNA or one or more coagulation-promoting fragments of RNA in amounts sufficient to promote coagulation and to promote fibrinolysis are described.

Abstract: Medicaments against thrombotic diseases are described which contain as an active ingredient the domain-5 of high molecular weight kininogen or a domain-5-peptide of the carboxy-terminal region of the high molecular weight kininogen. They are useful as thrombolytic or fibrinolytic agents or as agents against platelet aggregation as well as prophylactic agents against thromboembolic complication.

Abstract: A monoclonal antibody which inhibits the blood clotting factor VII-activating protease and its proenzyme and a blood clotting factor VII-activating protease, stabilized by the addition of said monoclonal antibody, and its proenzyme are described. A suitable monoclonal antibody is produced by hybridoma cell line DSM ACC 2533. The application of the inhibitory, monoclonal antibody in the stabilization of blood clotting preparations and in preparations for reducing the coagulability of the blood is disclosed.

Abstract: A device for supporting and electrically contacting brushes, with which an electrical loop contact can be established with slip-rings on a shaft of a current generator or an electric motor. The device includes a support having a support base and a plurality of pins fastened thereto, through which at least one brush can be connected supportively with the support base. The device has at least one current distributor which can be electrically contacted in a short-circuiting manner with at least two brushes and can be connected to at least one electrical connection line. More than one of the pins function as an electrical contact pin with a contact surface and are integral components of at least one current distributor, so that at least one brush can be connected supportively through it and electrically contacted. The supporting base is electrically insulated at least in regions of connecting locations to the contact pins.